Paul Tudor Jones’s CRISPR Therapeutics CRSP Stock Holding History

Paul Tudor Jones’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.24M	Sell	22,700 -700	-3%	-$36.9K	﹤0.01%	2253
2026 Q1	$1.11M	Sell	23,400 -24,600	-51%	-$1.3M	﹤0.01%	2291
2025 Q4	$2.52M	Sell	48,000 -16,400	-25%	-$982K	﹤0.01%	1644
2025 Q3	$4.17M	Buy	64,400 +17,300	+37%	+$993K	0.01%	1303
2025 Q2	$2.29M	Buy	47,100 +34,400	+271%	+$1.33M	0.01%	1570
2025 Q1	$432K	Buy	+12,700	New	+$538K	﹤0.01%	2366
2024 Q2	–	Sell	-20,300	Closed	-$1.38M	–	2387
2024 Q1	$1.38M	Sell	20,300 -600	-3%	-$43K	0.01%	1191
2023 Q4	$1.31M	Buy	+20,900	New	+$1.16M	0.01%	1319

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Paul Tudor Jones's CRSP Position: Q2 2026 in Review

Paul Tudor Jones reduced its CRISPR Therapeutics (CRSP) stake by 2.1% in Q2 2026, selling an estimated $47.4K and leaving 42,512 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

Paul Tudor Jones first reported a position in CRSP in Q1 2018 and has held it in 21 quarters since. The position peaked at $2.42M in Q4 2020. 520 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Paul Tudor Jones held 42,512 shares of CRISPR Therapeutics worth $2.32M as of Q2 2026.
Paul Tudor Jones sold 899 CRISPR Therapeutics shares in Q2 2026, an estimated $47.4K.
CRISPR Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1845 holding.
Paul Tudor Jones first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 21 quarters since.
Paul Tudor Jones's CRISPR Therapeutics position peaked at $2.42M in Q4 2020.
520 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.